Signal transduction therapy in haematological malignancies: Identification and targeting of tyrosine kinases

Clinical Science

Volumn 111, Issue 4, 2006, Pages 233-249

  Chase, Andrew ^a   Cross, Nicholas C P ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

BCR ABL; Haematological malignancy; Imatinib; Leukaemia; Signalling inhibitor; Tyrosine kinase

Indexed keywords

6 (2,6 DICHLOROPHENYL) 2 [3 (HYDROXYMETHYL)ANILINO] 8 METHYLPYRIDO[2,3 D]PYRIMIDIN 7(8H) ONE; [4 [2 CYCLOPENTYL 9 (3 HYDROXYPHENETHYL)PURIN 6 YLAMINO]PHENYL]DIMETHYLPHOSPHINE OXIDE; ANAPLASTIC LYMPHOMA KINASE; ANTIBIOTIC AGENT; AP 23848; BCR ABL PROTEIN; BOSUTINIB; CGP 76030; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; DASATINIB; ERBSTATIN; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FLT3 LIGAND; GELDANAMYCIN; HERBIMYCIN; IMATINIB; JANUS KINASE 2; NILOTINIB; NS 187; ON 012380; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PROTEINASE INHIBITOR; T 3151; UNCLASSIFIED DRUG;

CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DOSE RESPONSE; DRUG ACTIVITY; DRUG INHIBITION; DRUG MECHANISM; FGFRI GENE; FUSION GENE; GENE MUTATION; GENE TRANSLOCATION; HEMATOLOGIC MALIGNANCY; HUMAN; IC 50; MASTOCYTOSIS; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; HEMATOLOGIC NEOPLASMS; HUMANS; MUTATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 33750156289     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20060035     Document Type: Review

References (246)

1. Barbieri, M. A., Ramkumar, T. P., Fernadez-Pol, S., Chen, P. I. and Stahl, P. D. (2004) Receptor tyrosine kinase signaling and trafficking-paradigms revisited. Curr. Top. Microbiol. Immunol. 286, 1-20
2. Benmerah, A. (2004) Endocytosis: signaling from endocytic membranes to the nucleus. Curr. Biol. 14, R314-R316
3. Stachowiak, M. K., Fang, X., Myers, J. M. et al. (2003) Integrative nuclear FGFR1 signaling (INFS) as a part of a universal 'feed-forward-and-gate' signaling module that controls cell growth and differentiation. J. Cell Biochem. 90, 662-691
4. Melo, J. V. and Deininger, M. W. (2004) Biology of chronic myelogenous leukemia: signaling pathways of initiation and transformation. Hematol. Oncol. Clin. North Am. 18, 545-568
5. Steelman, L. S., Pohnert, S. C., Shelton, J. G., Franklin, R. A., Bertrand, F. E. and McCubrey, J. A. (2004) JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 18, 189-218
6. bcr/abl gene of the Philadelphia chromosome. Science 247, 824-830
7. bcr/abl protein. Proc. Natl. Acad. Sci. U.S.A. 85, 9312-9316
8. Uehara, Y., Hori, M., Takeuchi, T. and Umezawa, H. (1986) Phenotypic change from transformed to normal induced by benzoquinonoid ansamycins accompanies inactivation of p60src in rat kidney cells infected with Rous sarcoma virus. Mol. Cell. Biol. 6, 2198-2206
9. Uehara, Y., Hori, M., Takeuchi, T. and Umezawa, H. (1985) Screening of agents which convert 'transformed morphology' of Rous sarcoma virus-infected rat kidney cells to 'normal morphology': identification of an active agent as herbimycin and its inhibition of intracellular src kinase. Jpn J. Cancer Res. 76, 672-675
10. Richert, N., Davies, P. J., Jay, G. and Pastan, I. (1979) Inhibition of the transformation-specific kinase in ASV-transformed cells by N-α-tosyl-L-lysyl chloromethyl ketone. Cell 18, 369-374
11. Uehara, Y., Murakami, Y., Mizuno, S. and Kawai, S. (1988) Inhibition of transforming activity of tyrosine kinase oncogenes by herbimycin A. Virology 164, 294-298
12. Yaish, P., Gazit, A., Gilon, C. and Levitzki, A. (1988) Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science 242, 933-935
13. Anafi, M., Gazit, A., Gilon, C., Ben-Neriah, Y. and Levitzki, A. (1992) Selective interactions of transforming and normal abl proteins with ATP, tyrosine-copolymer substrates, and tyrphostins. J. Biol. Chem. 267, 4518-4523
14. Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B. and Kuriyan, J. (2000) Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289, 1938-1942
15. Buchdunger, E., Cioffi, C. L., Law, N. et al. (2000) Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther. 295, 139-145
16. Okuda, K., Weisberg, E., Gilliland, D. G. and Griffin, J. D. (2001) ARG tyrosine kinase activity is inhibited by STI571. Blood 97, 2440-2448
17. Dewar, A. L., Cambareri, A. C., Zannettino, A. C. et al. (2005) Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood 105, 3127-3132
18. bcr-abl tyrosine kinase activity induces K562 to differentiate. Blood 82, 3524-3529
19. Deininger, M. W., Goldman, J. M., Lydon, N. and Melo, J. V. (1997) The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 90, 3691-3698
20. Palacios, R. and Steinmetz, M. (1985) IL-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo. Cell 41, 727-734
21. Druker, B. J., Tamura, S., Buchdunger, E. et al. (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2, 561-566
22. Buchdunger, E., Zimmermann, J., Mett, H. et al. (1996) Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56, 100-104
23. Gleixner, K. V., Mayerhofer, M., Aichberger, K. J. et al. (2006) PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood 107, 752-759
24. Verstovsek, S., Golemovic, M., Kantarjian, H. et al. (2005) AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. Cancer 104, 1230-1236
25. Golemovic, M., Verstovsek, S., Giles, F. et al. (2005) AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin. Cancer Res. 11, 4941-4947
26. Weisberg, E., Manley, P. W., Breitenstein, W. et al. (2005) Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7, 129-141
27. Stover, E. H., Chen, J., Lee, B. H. et al. (2005) The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRβ and FIP1L1-PDGFRα in vitro and in vivo. Blood 106, 3206-3213
28. Schittenhelm, M. M., Shiraga, S., Schroeder, A. et al. (2006) Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. 66, 473-481
29. O'hare, T., Walters, D. K., Stoffregen, E. P. et al. (2005) In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 65, 4500-4505
30. Lombardo, L. J., Lee, F. Y., Chen, P. et al. (2004) Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl) -2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. 47, 6658-6661
31. Gumireddy, K., Baker, S. J., Cosenza, S. C. et al. (2005) A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc. Natl. Acad. Sci. U.S.A. 102, 1992-1997
32. Carter, T. A., Wodicka, L. M., Shah, N. P. et al. (2005) Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc. Natl. Acad. Sci. U.S.A. 102, 11011-11016
33. Corbin, A. S., Demehri, S., Griswold, I. J. et al. (2005) In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit. Blood 106, 227-234
34. O'hare, T., Pollock, R., Stoffregen, E. P. et al. (2004) Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. Blood 104, 2532-2539
35. O'hare, T., Walters, D. K., Stoffregen, E. P. et al. (2005) Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib. Clin. Cancer Res. 11, 6987-6993
36. Tatton, L., Morley, G. M., Chopra, R. and Khwaja, A. (2003) The Src-selective kinase inhibitor PP1 also inhibits Kit and Bcr-Abl tyrosine kinases. J. Biol. Chem. 278, 4847-4853
37. Warmuth, M., Simon, N., Mitina, O. et al. (2003) Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases. Blood 101, 664-672
38. Golas, J. M., Arndt, K., Etienne, C. et al. (2003) SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res. 63, 375-381
39. Kimura, S., Naito, H., Segawa, H. et al. (2005) NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 106, 3948-3954
40. Wolff, N. C., Veach, D. R., Tong, W. P., Bornmann, W. G., Clarkson, B. and Ilaria, Jr, R. L. (2005) PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia. Blood 105, 3995-4003
41. Corbin, A. S., Griswold, I. J., La, Rosee P. et al. (2004) Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970. Blood 104, 3754-3757
42. La, Rosee P., Corbin, A. S., Stoffregen, E. P., Deininger, M. W. and Druker, B. J. (2002) Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Res. 62, 7149-7153
43. Trudel, S., Li, Z. H., Wei, E. et al. (2005) CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 105, 2941-2948
44. Lopes de Menezes, D. E., Peng, J., Garrett, E. N. et al. (2005) CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia. Clin Cancer Res. 11, 5281-5291
45. Smith, B. D., Levis, M., Beran, M. et al. (2004) Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 103, 3669-3676
46. Sohal, J., Phan, V. T., Chan, P. V. et al. (2003) A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657. Blood 101, 3188-3197
47. Cain, J. A., Grisolano, J. L., Laird, A. D. and Tomasson, M. H. (2004) Complete remission of TEL-PDGFRB-induced myeloproliferative disease in mice by receptor tyrosine kinase inhibitor SU11657. Blood 104, 561-564
48. Chen, J., DeAngelo, D. J., Kutok, J. L. et al. (2004) PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc. Natl. Acad. Sci. U.S.A. 101, 14479-14484
49. Stam, R. W., den Boer, M. L., Schneider, P. et al. (2005) Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. Blood 106, 2484-2490
50. Fiedler, W., Serve, H., Dohner, H. et al. (2005) A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 105, 986-993
51. Yee, K. W., Schittenhelm, M., O'Farrell, A. M. et al. (2004) Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells 1. Blood 104, 4202-4209
52. Fiedler, W., Mesters, R., Tinnefeld, H. et al. (2003) A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood 102, 2763-2767
53. Clark, J. J., Cools, J., Curley, D. P. et al. (2004) Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518. Blood 104, 2867-2872
54. Komeno, Y., Kurokawa, M., Imai, Y. et al. (2005) Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase. Leukemia 19, 930-935
55. Adrian, F. J., Ding, Q., Sim, T. et al. (2006) Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat. Chem. Biol. 2, 95-102
56. Druker, B. J., Talpaz, M., Resta, D. J. et al. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031-1037
57. Druker, B. J., Sawyers, C. L., Kantarjian, H. et al. (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344, 1038-1042
58. Kantarjian, H. M., Talpaz, M., O'Brien, S. et al. (2002) Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-α: follow-up results. Clin. Cancer Res. 8, 2177-2187
59. Talpaz, M., Silver, R. T., Druker, B. J. et al. (2002) Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 99, 1928-1937
60. Sawyers, C. L., Hochhaus, A., Feldman, E. et al. (2002) Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99, 3530-3539
61. O'Brien, S. G., Guilhot, F., Larson, R. A. et al. (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348, 994-1004
62. Simonsson, B. (2006) Beneficial effects of cytogenetic and molecular response on long-term outcome in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM): update from the IRIS study. Blood 106, 52a
63. Gorre, M. E., Mohammed, M., Ellwood, K. et al. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876-880
64. Donato, N. J., Wu, J. Y., Stapley, J. et al. (2004) Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res. 64, 672-677
65. Hochhaus, A. and La, Rosee P. (2004) Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 18, 1321-1331
66. Martinelli, G., Soverini, S., Rosti, G., Cilloni, D. and Baccarani, M. (2005) New tyrosine kinase inhibitors in chronic myeloid leukemia. Haematologica 90, 534-541
67. Copland, M., Fraser, A. R., Harrison, S. J. and Holyoake, T. L. (2005) Targeting the silent minority: emerging immunotherapeutic strategies for eradication of malignant stem cells in chronic myeloid leukaemia. Cancer Immunol. Immunother. 54, 297-306
68. Hoover, R. R., Mahon, F. X., Melo, J. V. and Daley, G. Q. (2002) Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood 100, 1068-1071
69. Wardelmann, E., Thomas, N., Merkelbach-Bruse, S. et al. (2005) Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol. 6, 249-251
70. Kobayashi, S., Boggon, T. J., Dayaram, T. et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352, 786-792
71. Sawyers, C. L., Shah, N. P., Kantarjian, H. et al. (2005) A phase I study of BMS-354825 in patients with imatinib-resistant and intolerant accelerated and blast phase chronic myeloid leukemia (CML): Results from CA180002. J. Clin. Oncol. 23, 6520
72. Kantarjian, H., Ottmann, O. G., Cortes, J. et al. (2005) AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has significant activity in imatinib-resistant bcr-abl positive chronic myeloid leukemia (CML). J. Clin. Oncol. 23, 3014
73. Talpaz, M., Kantarjian, H., Paquette, R. et al. (2005) A phase I study of BMS-354825 in patients with imatinib-resistant and intolerant chronic phase chronic myeloid leukemia (CML): Results from CA180002. J. Clin. Oncol. 23, 6519
74. Walz, C. and Sattler, M. (2005) Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). Crit. Rev. Oncol. Hematol. 57, 145-164
75. Cortes, J. and Kantarjian, H. (2005) New targeted approaches in chronic myeloid leukemia. J. Clin. Oncol. 23, 6316-6324
76. Manley, P. W., Cowan-Jacob, S. W. and Mestan, J. (2005) Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia. Biochim. Biophys. Acta 1754, 3-13
77. Ottmann, O. G., Druker, B. J., Sawyers, C. L. et al. (2002) A phase 2 study of imatimb in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 100, 1965-1971
78. Lee, K. H., Lee, J. H., Choi, S. J. et al. (2005) Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 19, 1509-1516
79. Lee, S., Kim, Y. J., Min, C. K. et al. (2005) The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly-diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 105, 3449-3457
80. Yanada, M., Takeuchi, J., Sugiura, I. et al. (2006) High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly-diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J. Clin. Oncol. 24, 460-466
81. Delannoy, A., Lheritier, V., Thomas, X. et al. (2005) Treatment of Philadelphia-positive acute lymphocytic leukemia (Ph+ ALL) in the elderly with imatinib mesylate (STI571) and Chemotherapy. Blood 106, 46a
82. Kantarjian, H. M., Ottman, O., Corte, J. et al. (2006) AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has significant activity in imatinib-resistant chronic myeloid leukemia (CML) or Philadelphia-chromosome positive acute lymphoid leukemia (Ph+ ALL). Blood 106, 15a-16a
83. Sawyers, C. L., Kantarjian, H. M., Shah, N. P. et al. (2006) Dasatinib (BMS-354825) in patients with chronic myeloid Leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or intolerant to imatinib: update of a Phase I study. Blood 106, 16a
84. Ottmann, O. G., Giles, F., Hochhaus, A. et al. (2005) Activity of AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, in imatimb-resistant bcr-abl positive lymphoid malignancies. J. Clin. Oncol. 23, 3015
85. O'Brien, S. G., Vieira, S. A., Connors, S. et al. (2002) Transient response to imatinib mesylate (STI571) in a patient with the ETV6-ABL t(9;12) translocation. Blood 99, 3465-3467
86. Barbouti, A., Ahlgren, T., Johansson, B. et al. (2003) Clinical and genetic studies of ETV6/ABL1-positive chronic myeloid leukaemia in blast crisis treated with imatinib mesylate. Br. J. Haematol. 122, 85-93
87. Tirado, C. A., Sebastian, S., Moore, J. O., Gong, J. Z. and Goodman, B. K. (2005) Molecular and cytogenetic characterization of a novel rearrangement involving chromosomes 9, 12, and 17 resulting in ETV6 (TEL) and ABL fusion. Cancer Genet. Cytogenet. 157, 74-77
88. Meyer-Monard, S., Muhlematter, D., Streit, A. et al. (2005) Broad molecular screening of an unclassifiable myeloproliferative disorder reveals an unexpected ETV6/ABL1 fusion transcript. Leukemia 19, 1096-1099
89. De Keersmaecker, K., Graux, C., Odero, M. D. et al. (2005) Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32). Blood 105, 4849-4852
90. Graux, C., Cools, J., Melotte, C. et al. (2004) Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat. Genet. 36, 1084-1089
91. Barber, K. E., Martineau, M., Harewood, L. et al. (2004) Amplification of the ABL gene in T-cell acute lymphoblastic leukemia. Leukemia 18, 1153-1156
92. Bernasconi, P., Calatroni, S., Giardini, I. et al. (2005) ABL1 amplification in T-cell acute lymphoblastic leukemia. Cancer Genet. Cytogenet. 162, 146-150
93. Ballerini, P., Busson, M., Fasola, S. et al. (2005) NUP214-ABL1 amplification in t(5;14)/HOX11L2-positive ALL present with several forms and may have a prognostic significance. Leukemia 19, 468-470
94. Stergianou, K., Fox, C. and Russell, N. H. (2005) Fusion of NUP214 to ABL1 on amplified episomes in T-ALL: implications for treatment. Leukemia 19, 1680-1681
95. Schaller, J. L. and Burkland, G. A. (2001) Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. Med. Gen. Med. 3, 9
96. Gleich, G. J., Leiferman, K. M., Pardanani, A., Tefferi, A. and Butterfield, J. H. (2002) Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 359, 1577-1578
97. Cools, J., DeAngelo, D. J., Gotlib, J. et al. (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 348, 1201-1214
98. Griffin, J. H., Leung, J., Bruner, R. J., Caligiuri, M. A. and Briesewitz, R. (2003) Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc. Natl. Acad. Sci. U.S.A. 100, 7830-7835
99. Pardanani, A., Brockman, S. R., Paternoster, S. F. et al. (2004) FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 104, 3038-3045
100. Klion, A. D., Robyn, J., Akin, C. et al. (2004) Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 103, 473-478
101. Bain, B. J. (2004) Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis. Am. J. Hematol. 77, 82-85
102. Gotlib, J., Cools, J., Malone, III, J. M., Schrier, S. L., Gilliland, D. G. and Coutre, S. E. (2004) The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 103, 2879-2891
103. Pardanani, A., Ketterling, R. P., Li, C. Y. et al. (2006) FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk. Res. 30, 965-970
104. Martinelli, G., Malagola, M., Ottaviani, E., Rosti, G., Trabacchi, E. and Baccarani, M. (2004) Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome. Haematologica 89, 236-237
105. Cools, J., Stover, E. H., Boulton, C. L. et al. (2003) PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease. Cancer Cell 3, 459-469
106. Ho, C. Y., Ludovici, D. W., Maharoof, U. S. et al. (2005) (6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad antiproliferative activity against tumor cells. J. Med. Chem. 48, 8163-8173
107. Baxter, E. J., Kulkarni, S., Vizmanos, J. L. et al. (2003) Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders. Br. J. Haematol. 120, 251-256
108. Trempat, P., Villalva, C., Laurent, G. et al. (2003) Chronic myeloproliferative disorders with rearrangement of the platelet-derived growth factor α receptor: a new clinical target for STI571/Glivec. Oncogene 22, 5702-5706
109. Safley, A. M., Sebastian, S., Collins, T. S. et al. (2004) Molecular and cytogenetic characterization of a novel translocation t(4;22) involving the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with atypical chronic myeloid leukemia. Genes Chromosomes Cancer 40, 44-50
110. Golub, T. R., Barker, G. F., Lovett, M. and Gilliland, D. G. (1994) Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 77, 307-316
111. Steer, E. J. and Cross, N. C. (2002) Myeloproliferative disorders with translocations of chromosome 5q31-5q35: role of the platelet-derived growth factor receptor β. Acta Haematol. 107, 113-122
112. Abe, A., Emi, N., Tanimoto, M., Terasaki, H., Marunouchi, T. and Saito, H. (1997) Fusion of the platelet-derived growth factor receptor beta to a novel gene CEV14 in acute myelogenous leukemia after clonal evolution. Blood 90, 4271-4277
113. Ross, T. S., Bernard, O. A., Berger, R. and Gilliland, D. G. (1998) Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor β receptor (PDGFβR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2). Blood 91, 4419-4426
114. Gunby, R. H., Cazzaniga, G., Tassi, E. et al. (2003) Sensitivity to imatinib but low frequency of the TEL/PDGFRβ fusion protein in chronic myelomonocytic leukemia. Haematologica 88, 408-415
115. Kulkarni, S., Heath, C., Parker, S. et al. (2000) Fusion of H4/D10S170 to the platelet-derived growth factor receptor β in BCR-ABL-negative myeloproliferative disorders with a t(5;10)(q33;q21). Cancer Res. 60, 3592-3598
116. Schwaller, J., Anastasiadou, E., Cain, D. et al. (2001) H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor β gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22). Blood 97, 3910-3918
117. Garcia, J. L., Font, de Mora, Hernandez, J. M. et al. (2003) Imatinib mesylate elicits positive clinical response in atypical chronic myeloid leukemia involving the platelet-derived growth factor receptor β. Blood 102, 2699-2700
118. Magnusson, M. K., Meade, K. E., Brown, K. E. et al. (2001) Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia. Blood 98, 2518-2525
119. Wilkinson, K., Velloso, E. R., Lopes, L. F. et al. (2003) Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib. Blood 102, 4187-4190
120. Levine, R. L., Wadleigh, M., Sternberg, D. W. et al. (2005) KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32). Leukemia 19, 27-30
121. Grand, F. H., Burgstaller, S., Ruhr, T. et al. (2004) p53-Binding protein 1 is fused to the platelet-derived growth factor receptor β in a patient with a t(5;15)(q33;q22) and an imatinib-responsive eosinophilic myeloproliferative disorder. Cancer Res. 64, 7216-7219
122. Morerio, C., Acquila, M., Rosanda, C. et al. (2004) HCMOGT-1 is a novel fusion partner to PDGFRB in juvenile myelomonocytic leukemia with t(5;17)(q33;p11.2). Cancer Res. 64, 2649-2651
123. Vizmanos, J. L., Novo, F. J., Roman, J. P. et al. (2004) NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorder. Cancer Res. 64, 2673-2676
124. Carroll, M., Ohno-Jones, S., Tamura, S. et al. (1997) CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 90, 4947-4952
125. Apperley, J. F., Gardembas, M., Melo, J. V. et al. (2002) Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor β. N. Engl. J. Med. 347, 481-487
126. Wittman, B., Horan, J., Baxter, J. et al. (2004) A 2-year-old with atypical CML with a t(5;12)(q33;p13) treated successfully with imatinib mesylate. Leuk. Res. 28 (Suppl. 1), S65-S69
127. Bastie, J. N., Garcia, I., Terre, C., Cross, N. C., Mahon, F. X. and Castaigne, S. (2004) Lack of response to imatinib mesylate in a patient with accelerated phase myeloproliferative disorder with rearrangement of the platelet-derived growth factor receptor β-gene. Haematologica 89, 1263-1264
128. Andrejauskas-Buchdunger, E. and Regenass, U. (1992) Differential inhibition of the epidermal growth factor-, platelet-derived growth factor-, and protein kinase C-mediated signal transduction pathways by the staurosporine derivative CGP 41251. Cancer Res. 52, 5353-5358
129. Chen, J., Wall, N. R., Kocher, K. et al. (2004) Stable expression of small interfering RNA sensitizes TEL-PDGFβR to inhibition with imatinib or rapamycin. J. Clin. Invest 113, 1784-1791
130. Besmer, P., Murphy, J. E., George, P. C. et al. (1986) A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family. Nature (London) 320, 415-421
131. Yarden, Y., Kuang, W. J., Yang-Feng, T. et al. (1987) Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J. 6, 3341-3351
132. Heinrich, M. C., Corless, C. L., Demetri, G. D. et al. (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 21, 4342-4349
133. Kemmer, K., Corless, C. L., Fletcher, J. A. et al. (2004) KIT mutations are common in testicular seminomas. Am. J. Pathol. 164, 305-313
134. Furitsu, T., Tsujimura, T., Tono, T. et al. (1993) Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J. Clin. Invest. 92, 1736-1744
135. Nagata, H., Worobec, A. S., Oh, C. K. et al. (1995) Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc. Natl. Acad. Sci. U.S.A. 92, 10560-10564
136. Longley, Jr, B. J., Metcalfe, D. D., Tharp, M. et al. (1999) Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc. Natl. Acad. Sci. U.S.A. 96, 1609-1614
137. Akin, C. (2005) Clonality and molecular pathogenesis of mastocytosis. Acta Haematol. 114, 61-69
138. Akin, C., Fumo, G., Yavuz, A. S., Lipsky, P. E., Neckers, L. and Metcalfe, D. D. (2004) A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 103, 3222-3225
139. Pignon, J. M., Giraudier, S., Duquesnoy, P. et al. (1997) A new c-kit mutation in a case of aggressive mast cell disease. Br. J. Haematol. 96, 374-376
140. Hartmann, K., Wardelmann, E., Ma, Y. et al. (2005) Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis. Gastroenterology 129, 1042-1046
141. Tang, X., Boxer, M., Drummond, A., Ogston, P., Hodgins, M. and Burden, A. D. (2004) A germline mutation in KIT in familial diffuse cutaneous mastocytosis. J. Med. Genet. 41, e88
142. Zhang, L. Y., Smith, M. L., Schultheis, B. et al. (2006) A novel K509I mutation of KIT identified in familial mastocytosis: in vitro and in vivo responsiveness to imatinib therapy. Leuk. Res. 30, 373-378
143. Gotlib, J., Berube, C., Growney, J. D. et al. (2005) Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 106, 2865-2870
144. von Bubnoff, N., Gorantla, S. H., Kancha, R. K., Lordick, F., Peschel, C. and Duyster, J. (2005) The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107. Leukemia 19, 1670-1671
145. D816V, an imatinib-resistant activating mutation that triggers neoplastic growth in the majority of patients with systemic mastocytosis. Blood 108, 286-291
146. Growney, J. D., Clark, J. J., Adelsperger, J. et al. (2005) Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood 106, 721-724
147. Gotlib, J., Berube, C., Growney, J. D. et al. (2005) Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 106, 2865-2870
148. Gari, M., Goodeve, A., Wilson, G. et al. (1999) c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. Br. J. Haematol. 105, 894-900
149. Beghini, A., Ripamonti, C. B., Cairoli, R. et al. (2004) KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication. Haematologica 89, 920-925
150. Cairoli, R., Beghini, A., Grillo, G. et al. (2005) Prognostic impact of c-KIT mutations in core binding factor leukemias. an Italian retrospective study. Blood 107, 3463-3468
151. Wang, Y. Y., Zhou, G. B., Yin, T. et al. (2005) AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. Proc. Natl. Acad. Sci. U.S.A. 102, 1104-1109
152. Nanri, T., Matsuno, N., Kawakita, T. et al. (2005) Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22). Leukemia 19, 1361-1366
153. Beghini, A., Cairoli, R., Morra, E. and Larizza, L. (1998) In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation. Blood Cells Mol. Dis. 24, 262-270
154. Pullarkat, V. A., Pullarkat, S. T., Calverley, D. C. and Brynes, R. K. (2000) Mast cell disease associated with acute myeloid leukemia: detection of a new c-kit mutation Asp816His. Am. J. Hematol. 65, 307-309
155. Schnittger, S., Kohl, T. M., Haferlach, T. et al. (2006) KIT-D816
156. Shimada, A., Taki, T., Tabuchi, K. et al. (2006) KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group. Blood 107, 1806-1809
157. Kindler, T., Breitenbuecher, F., Marx, A. et al. (2004) Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia. Blood 103, 3644-3654
158. Malagola, M., Martinelli, G., Rondini, M. et al. (2005) Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target? Blood 105, 904
159. Cairoli, R., Beghini, A., Morello, E. et al. (2005) Imatinib mesylate in the treatment of core binding factor leukemias with KIT mutations: a report of three cases. Leuk. Res. 29, 397-400
160. Nanri, T., Matsuno, N., Kawakita, T., Mitsuya, H. and Asou, N. (2005) Imatinib mesylate for refractory acute myeloblastic leukemia harboring inv(16) and a C-KIT exon 8 mutation. Leukemia 19, 1673-1675
161. Mesters, R. M., Padro, T., Bieker, R. et al. (2001) Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia. Blood 98, 241-243
162. Kindler, T., Breitenbuecher, F., Marx, A. et al. (2003) Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML. Blood 101, 2960-2962
163. Xiao, S., Nalabolu, S. R., Aster, J. C. et al. (1998) FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. Nat. Genet. 18, 84-87
164. Smedley, D., Hamoudi, R., Clark, J. et al. (1998) The t(8;13)(p11;q11-q12) rearrangement associated with an atypical myeloproliferative disorder fuses the fibroblast growth factor receptor 1 gene to a novel gene RAMP. Hum. Mol. Genet. 7, 637-642
165. Popovici, C., Adelaide, J., Ollendorff, V. et al. (1998) Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13). Proc. Natl. Acad. Sci. U.S.A. 95, 5712-5717
166. Reiter, A., Sohal, J., Kulkarni, S. et al. (1998) Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the t(8;13)(p11;q12) myeloproliferative syndrome. Blood 92, 1735-1742
167. Murati, A., Arnoulet, C., Lafage-Pochitaloff, M. et al. (2005) Dual lympho-myeloproliferative disorder in a patient with t(8;22) with BCR-FGFR1 gene fusion. Int. J. Oncol. 26, 1485-1492
168. Fioretos, T., Panagopoulos, I., Lassen, C. et al. (2001) Fusion of the BCR and the fibroblast growth factor receptor-1 (FGFR1) genes as a result of t(8;22)(p11;q11) in a myeloproliferative disorder: the first fusion gene involving BCR but not ABL. Genes Chromosomes Cancer 32, 302-310
169. Pini, M., Gottardi, E., Scaravaglio, P. et al. (2002) A fourth case of BCR-FGFR1 positive CML-like disease with t(8;22) translocation showing an extensive deletion on the derivative chromosome 8p. Hematol. J. 3, 315-316
170. Belloni, E., Trubia, M., Gasparini, P. et al. (2005) 8p11 myeloproliferative syndrome with a novel t(7;8) translocation leading to fusion of the FGFR1 and TIF1 genes. Genes Chromosomes Cancer 42, 320-325
171. Walz, C., Chase, A., Schoch, C. et al. (2005) The t(8;17)(p11;q23) in the 8p11 myeloproliferative syndrome fuses MYO18A to FGFR1. Leukemia 19, 1005-1009
172. Guasch, G., Mack, G. J., Popovici, C. et al. (2000) FGFR1 is fused to the centrosome-associated protein CEP110 in the 8p12 stem cell myeloproliferative disorder with t(8;9)(p12;q33). Blood 95, 1788-1796
173. Popovici, C., Zhang, B., Gregoire, M. J. et al. (1999) The t(6;8)(q27;p11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to fibroblast growth factor receptor 1. Blood 93, 1381-1389
174. Vizmanos, J. L., Hernandez, R., Vidal, M. J. et al. (2004) Clinical variability of patients with the t(6;8)(q27;p12) and FGFR1OP-FGFR1 fusion: two further cases. Hematol. J. 5, 534-537
175. Grand, E. K., Grand, F. H., Chase, A. J. et al. (2003) Identification of a novel gene, FGFR1OP2, fused to FGFR1 in the 8p11 myeloproliferative syndrome. Genes Chromosomes Cancer 40, 78-83
176. Guasch, G., Popovici, C., Mugneret, F. et al. (2003) Endogenous retroviral sequence is fused to FGFR1 kinase in the 8p12 stem-cell myeloproliferative disorder with t(8;19)(p12;q13.3). Blood 101, 286-288
177. Grand, E. K., Chase, A. J., Heath, C., Rahemtulla, A. and Cross, N. C. (2004) Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074. Leukemia 18, 962-966
178. Sibley, K., Fenton, J. A., Dring, A. M., Ashcroft, A. J., Rawstron, A. C. and Morgan, G. J. (2002) A molecular study of the t(4;14) in multiple myeloma. Br. J. Haematol. 118, 514-520
179. Yagasaki, F., Wakao, D., Yokoyama, Y. et al. (2001) Fusion of ETV6 to fibroblast growth factor receptor 3 in peripheral T-cell lymphoma with a t(4;12)(p16;p13) chromosomal translocation. Cancer Res. 61, 8371-8374
180. Paterson, J. L., Li, Z., Wen, X. Y. et al. (2004) Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma. Br. J. Haematol. 124, 595-603
181. Chen, J., Lee, B. H., Williams, I. R. et al. (2005) FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies. Oncogene 24, 8259-8267
182. Nakao, M., Yokota, S., Iwai, T. et al. (1996) Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 10, 1911-1918
183. Kiyoi, H., Naoe, T., Nakano, Y. et al. (1999) Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 93, 3074-3080
184. Kottaridis, P. D., Gale, R. E., Frew, M. E. et al. (2001) The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98, 1752-1759
185. Meshinchi, S., Woods, W. G., Stirewalt, D. L. et al. (2001) Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood 97, 89-94
186. Schnittger, S., Schoch, C., Dugas, M. et al. (2002) Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 100, 59-66
187. Thiede, C., Steudel, C., Mohr, B. et al. (2002) Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99, 4326-4335
188. Abu-Duhier, F. M., Goodeve, A. C., Wilson, G. A., Care, R. S., Peake, I. R. and Reilly, J. T. (2001) Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br. J. Haematol. 113, 983-988
189. Yamamoto, Y., Kiyoi, H., Nakano, Y. et al. (2001) Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 97, 2434-2439
190. Stirewalt, D. L., Meshinchi, S., Kussick, S. J. et al. (2004) Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukaemia. Br. J. Haematol. 124, 481-484
191. Reindl, C., Bagrintseva, K., Vempati, S. et al. (2006) Point mutations found in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML. Blood 107, 3700-3709
192. Mead, A., Linch, D., Hills, R., Wheatley, K., Burnett, A. K. and Gale, R. E. (2006) Favourable prognosis associated with FLT3 tyrosine kinase domain mutations in AML in contrast to the adverse outcome associated with internal tandem duplications. Blood 106, 101a
193. O'Farrell, A. M., Foran, J. M., Fiedler, W. et al. (2003) An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin. Cancer Res. 9, 5465-5476
194. Lopes de Menezes, D. E., Peng, J., Garrett, E. N. et al. (2005) CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia. Clin Cancer Res. 11, 5281-5291
195. Stone, R. M., DeAngelo, D. J., Klimek, V. et al. (2005) Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 105, 54-60
196. Stone, R., Fischer, T., Paquette, R. et al. (2006) Phase IB study of PKC412, an oral FLT3 kinase inhibitor, in sequential and simultaneous combinations with daunorubicin and cytarabine (DA) induction and high-dose cytarabine consolidation in newly diagnosed patients with AML. Blood 106, 121a-122a
197. Levis, M., Smith, B. D., Beran, M. et al. (2006) A Randomized, open-label study of lestaurtinib (CEP-701), an oral FLT3 inhibitor, administered in sequence with chemotherapy in patients with relapsed AML harboring FLT3 activating mutations: clinical response correlates with successful FLT3 inhibition. Blood 106, 121a
198. Taketani, T., Taki, T., Sugita, K. et al. (2004) FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy. Blood 103, 1085-1088
199. Armstrong, S. A., Kung, A. L., Mabon, M. E. et al. (2003) Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 3, 173-183
200. Armstrong, S. A., Mabon, M. E., Silverman, L. B. et al. (2004) FLT3 mutations in childhood acute lymphoblastic leukemia. Blood 103, 3544-3546
201. Paietta, E., Ferrando, A. A., Neuberg, D. et al. (2004) Activating FLT3 mutations in CD117/KIT(+) T-cell acute lymphoblastic leukemias. Blood 104, 558-560
202. Van Vlierberghe, P., Meijerink, J. P., Stam, R. W. et al. (2005) Activating FLT3 mutations in CD4+/CD8-pediatric T-cell acute lymphoblastic leukemias. Blood 106, 4414-4415
203. James, C., Ugo, V., Le Couedic, J. P. et al. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature (London) 434, 1144-1148
204. Baxter, E. J., Scott, L. M., Campbell, P. J. et al. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365, 1054-1061
205. Levine, R. L., Wadleigh, M., Cools, J. et al. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7. 387-397
206. Kralovics, R., Passamonti, F., Buser, A. S. et al. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352, 1779-1790
207. Zhao, R., Xing, S., Li, Z. et al. (2005) Identification of an acquired JAK2 mutation in Polycythemia vera. J. Biol. Chem. 280, 22788-22792
208. Steensma, D. P., Dewald, G. W., Lasho, T. L. et al. (2005) The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both 'atypical' myeloproliferative disorders and the myelodysplastic syndrome. Blood 106, 1207-1209
209. Jones, A. V., Kreil, S., Zoi, K. et al. (2005) Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106, 2162-2168
210. Jelinek, J., Oki, Y., Gharibyan, V. et al. (2005) JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia-chromosome negative CML and megakaryocytic leukemia. Blood 106, 3370-3373
211. Saemann, M. D., Zeyda, M., Stulnig, T. M. et al. (2004) Janus kinase-3 (JAK3) inhibition: a novel immunosuppressive option for allogeneic transplantation. Transpl. Int. 17, 481-489
212. Silver, R. T., Fruchtman, S. M., Feldman, E., Spivak, J. L. and Salvado, A. J. (2004) Imatinib mesylate (GLEEVEC) is effective in the treatment of Polycythemia vera: a multi-institutional clinical trial. Blood 104, 4747a
213. Silver, R. T. (2005) Treatment of polycythemia vera with recombinant interferon α (rIFNα) or imatinib mesylate. Curr. Hematol. Rep. 4, 235-237
214. Jones, A. V., Silver, R. T., Waghorn, K. et al. (2006) Minimal molecular response in polycythemia vera patients treated with imatinib or interferon α. Blood 107, 3339-3341
215. Lacronique, V., Boureux, A., Valle, V. D. et al. (1997) A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 278, 1309-1312
216. Peeters, P., Raynaud, S. D., Cools, J. et al. (1997) Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 90, 2535-2540
217. Griesinger, F., Hennig, H., Hillmer, F. et al. (2005) A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia. Genes Chromosomes Cancer 44, 329-333
218. Reiter, A., Walz, C., Watmore, A. et al. (2005) The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res. 65, 2662-2667
219. Bousquet, M., Quelen, C., De Mas, V. et al. (2005) The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene. Oncogene 24, 7248-7252
220. Murati, A., Gelsi-Boyer, V., Adelaide, J. et al. (2005) PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation. Leukemia 19, 1692-1696
221. Adelaide, J., Perot, C., Gelsi-Boyer, V. et al. (2006) A t(8;9) translocation with PCM1-JAK2 fusion in a patient with T-cell lymphoma. Leukemia 20, 536-537
222. Pulford, K., Morris, S. W. and Turturro, F. (2004) Anaplastic lymphoma kinase proteins in growth control and cancer. J. Cell. Physiol. 199, 330-358
223. De Paepe, P., Baens, M., van Krieken, H. et al. (2003) ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma. Blood 102, 2638-2641
224. Gascoyne, R. D., Lamant, L., Martin-Subero, J. I. et al. (2003) ALK-positive diffuse large B-cell lymphoma is associated with clathrin-ALK rearrangements: report of 6 cases. Blood 102, 2568-2573
225. Lawrence, B., Perez-Atayde, A., Hibbard, M. K. et al. (2000) TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. Am. J. Pathol. 157, 377-384
226. Argani, P., Lui, M. Y., Couturier, J., Bouvier, R., Fournet, J. C. and Ladanyi, M. (2003) A novel CLTC-TFE3 gene fusion in pediatric renal adenocarcinoma with t(X;17)(p11.2;q23). Oncogene 22, 5374-5378
227. Ma, Z., Hill, D. A., Collins, M. H. et al. (2003) Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 37, 98-105
228. Debelenko, L. V., Arthur, D. C., Pack, S. D., Helman, L. J., Schrump, D. S. and Tsokos, M. (2003) Identification of CARS-ALK fusion in primary and metastatic lesions of an inflammatory myofibroblastic tumor. Lab. Invest. 83, 1255-1265
229. Panagopoulos, I., Nilsson, T., Domanski, H. A. et al. (2006) Fusion of the SEC31L1 and ALK genes in an inflammatory myofibroblastic tumor. Int. J. Cancer 118, 1181-1186
230. Pulford, K., Roberton, H. M. and Jones, M. (2005) Antibody techniques used in the study of anaplastic lymphoma kinase-positive ALCL. Methods Mol. Med. 115, 271-294
231. Wan, W., Albom, M. S., Lu, L. et al. (2005) Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large cell lymphoma cells. Blood 107, 1617-1623
232. Hosoya, N., Qiao, Y., Hangaishi, A. et al. (2005) Identification of a SRC-like tyrosine kinase gene, FRK, fused with ETV6 in a patient with acute myelogenous leukemia carrying a t(6;12)(q21;p13) translocation. Genes Chromosomes Cancer 42, 269-279
233. Tycko, B., Smith, S. D. and Sklar, J. (1991) Chromosomal translocations joining LCK and TCRB loci in human T cell leukemia. J. Exp. Med. 174, 867-873
234. Cazzaniga, G., Tosi, S., Aloisi, A. et al. (1999) The tyrosine kinase abl-related gene ARG is fused to ETV6 in an AML-M4Eo patient with a t(1;12)(q25;p13): molecular cloning of both reciprocal transcripts. Blood 94, 4370-4373
235. Iijima, Y., Ito, T., Oikawa, T. et al. (2000) A new ETV6/TEL partner gene, ARG (ABL-related gene or ABL2), identified in an AML-M3 cell line with a t(1;12)(q25;p13) translocation. Blood 95, 2126-2131
236. Griesinger, F., Janke, A., Podleschny, M. and Bohlander, S. K. (2002) Identification of an ETV6-ABL2 fusion transcript in combination with an ETV6 point mutation in a T-cell acute lymphoblastic leukaemia cell line. Br. J. Haematol. 119, 454-458
237. Streubel, B., Vinatzer, U., Willheim, M., Raderer, M. and Chott, A. (2005) Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma. Leukemia 20, 313-318
238. Kuno, Y., Abe, A., Emi, N. et al. (2001) Constitutive kinase activation of the TEL-Syk fusion gene in myelodysplastic syndrome with t(9;12)(q22;p12). Blood 97, 1050-1055
239. Eguchi, M., Eguchi-Ishimae, M., Tojo, A. et al. (1999) Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25). Blood 93, 1355-1363
240. Knezevich, S. R., McFadden, D. E., Tao, W., Lim, J. F. and Sorensen, P. H. (1998) A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat. Genet. 18, 184-187
241. Rubin, B. P., Chen, C. J., Morgan, T. W. et al. (1998) Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma. Am. J. Pathol. 153, 1451-1458
242. Tognon, C., Knezevich, S. R., Huntsman, D. et al. (2002) Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2, 367-376
243. Uren, A. and Toretsky, J. A. (2005) Pediatric malignancies provide unique cancer therapy targets. Curr. Opin. Pediatr. 17, 14-19
244. Lai, J. Y., Cox, P. J., Patel, R. et al. (2003) Potent small molecule inhibitors of spleen tyrosine kinase (Syk). Bioorg. Med. Chem. Lett. 13, 3111-3114
245. Rinaldi, A., Kwee, I., Taborelli, M. et al. (2006) Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br. J. Haematol. 132, 303-316
246. Tan, A. Y., Westerman, D. A., Lynch, K. P., Grant, A., McArthur, G. A. and Dobrovic, A. (2005) Novel methods for the sensitive detection of c-KIT D816V and other exon 17 mutations in patients with mastocytosis. Blood 106, 915a